JP2024503635A5 - - Google Patents
Info
- Publication number
- JP2024503635A5 JP2024503635A5 JP2023541262A JP2023541262A JP2024503635A5 JP 2024503635 A5 JP2024503635 A5 JP 2024503635A5 JP 2023541262 A JP2023541262 A JP 2023541262A JP 2023541262 A JP2023541262 A JP 2023541262A JP 2024503635 A5 JP2024503635 A5 JP 2024503635A5
- Authority
- JP
- Japan
- Prior art keywords
- pro
- cys
- pharmaceutically acceptable
- solvate
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21150562.3A EP4050018A1 (en) | 2021-01-07 | 2021-01-07 | Compounds comprising a fibroblast activation protein ligand and use thereof |
| EPEP21150562 | 2021-01-07 | ||
| PCT/EP2022/050294 WO2022148851A1 (en) | 2021-01-07 | 2022-01-07 | Compounds comprising a fibroblast activation protein ligand and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024503635A JP2024503635A (ja) | 2024-01-26 |
| JP2024503635A5 true JP2024503635A5 (https=) | 2025-01-16 |
Family
ID=74215696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023541262A Pending JP2024503635A (ja) | 2021-01-07 | 2022-01-07 | 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240115745A1 (https=) |
| EP (2) | EP4050018A1 (https=) |
| JP (1) | JP2024503635A (https=) |
| KR (1) | KR20230129260A (https=) |
| CN (1) | CN116940586A (https=) |
| AU (1) | AU2022205776A1 (https=) |
| CA (1) | CA3206481A1 (https=) |
| IL (1) | IL303926A (https=) |
| WO (1) | WO2022148851A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3997103T3 (fi) | 2019-07-08 | 2025-02-03 | 3B Pharmaceuticals Gmbh | Fibroblastien aktivaatioproteiinin ligandia käsittäviä yhdisteitä ja niiden käyttö |
| EP4475900A1 (en) | 2022-02-09 | 2024-12-18 | Novartis AG | Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent |
| US20250270238A1 (en) * | 2022-05-20 | 2025-08-28 | The Governors Of The University Of Alberta | A new bifunctional linchpin that reacts selectively with cysteine residues to invoke cyclization while concurrently introducing a dotaga moiety for radiometal chelation |
| PE20251640A1 (es) * | 2022-09-07 | 2025-06-24 | 3B Pharmaceuticals Gmbh | Ligandos de antigeno de membrana especifica de la prostata (psma) y uso de los mismos |
| IL322552A (en) * | 2023-02-10 | 2025-10-01 | Chengdu New Radiomedicine Tech Co Ltd | Polypeptide compound and its use |
| WO2024198838A1 (zh) * | 2023-03-27 | 2024-10-03 | 晶核生物医药科技(南京)有限公司 | 环状多肽类化合物及其应用 |
| KR20260026051A (ko) * | 2023-06-14 | 2026-02-25 | 마리아나 온콜로지 인크. | Dll3 표적화 펩티드 및 이의 구성체 |
| CN121712788A (zh) * | 2023-06-14 | 2026-03-20 | 马里亚纳肿瘤学公司 | 靶向dll3的肽及其构建体 |
| CN121712787A (zh) * | 2023-06-14 | 2026-03-20 | 马里亚纳肿瘤学公司 | 靶向dll3的肽及其构建体 |
| WO2025082283A1 (zh) * | 2023-10-16 | 2025-04-24 | 四川科伦博泰生物医药股份有限公司 | 环肽结构的配体化合物及其核素标记物、药物组合物及应用 |
| GB202318958D0 (en) * | 2023-12-12 | 2024-01-24 | King S College London | Compound |
| WO2025163556A1 (en) | 2024-02-01 | 2025-08-07 | Novartis Ag | Methods for treating cancer |
| WO2025179168A1 (en) * | 2024-02-22 | 2025-08-28 | Mariana Oncology Inc. | Synthesis of dll3-binding peptides |
| WO2026017046A1 (zh) * | 2024-07-19 | 2026-01-22 | 晶核生物医药科技(南京)有限公司 | 一种环多肽、其制备方法和应用 |
| WO2026021314A1 (zh) * | 2024-07-22 | 2026-01-29 | 山东威智知科药业有限公司 | Fap化合物及其用途 |
| CN120590466A (zh) * | 2025-08-06 | 2025-09-05 | 首都医科大学脑重大疾病研究中心(北京脑重大疾病研究院) | 一种靶向成纤维细胞活化蛋白的化合物及其应用 |
| CN121045338A (zh) * | 2025-11-05 | 2025-12-02 | 原子高科股份有限公司 | 一种靶向caix的环肽及其制备方法与应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4885363A (en) | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| US5021556A (en) | 1987-07-22 | 1991-06-04 | Neorx Corporation | Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides |
| US5075099A (en) | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| US5367080A (en) | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
| US5965107A (en) | 1992-03-13 | 1999-10-12 | Diatide, Inc. | Technetium-99m labeled peptides for imaging |
| US5886142A (en) | 1997-05-20 | 1999-03-23 | Thomas Jefferson University | Radiolabeled thrombus imaging agents |
| ATE357509T1 (de) | 1997-09-29 | 2007-04-15 | Point Therapeutics Inc | Stimulierung von hämatopoietischen zellen im vitro |
| EP0953639A1 (en) | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
| US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
| EP1268550A2 (en) | 2000-03-17 | 2003-01-02 | Boehringer Ingelheim Pharma KG | Human fap-alpha-specific antibodies |
| US7374898B2 (en) | 2004-10-12 | 2008-05-20 | The Research Foundation Of State University Of New York | Peptide inhibitors against seprase |
| US7399869B2 (en) | 2005-05-19 | 2008-07-15 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
| US8933201B2 (en) | 2006-06-07 | 2015-01-13 | The Board Of Regents Of The University Of Oklahoma | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use |
| WO2008116054A1 (en) | 2007-03-20 | 2008-09-25 | Trustees Of Tufts College | Inhibitors of fibroblast activation protein, and methods of use thereof |
| EP2100900A1 (en) | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
| WO2010036814A1 (en) | 2008-09-25 | 2010-04-01 | Molecular Insight Pharmaceuticals, Inc. | Selective seprase inhibitors |
| CA2776037A1 (en) | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd | Anti-fibroblast activation protein antibodies and methods and uses thereof |
| CA2806021C (en) | 2010-08-13 | 2019-05-21 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
| WO2013107820A1 (en) | 2012-01-17 | 2013-07-25 | Universiteit Antwerpen | Novel fap inhibitors |
| UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| GB201402006D0 (en) | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
| WO2016146174A1 (en) * | 2015-03-17 | 2016-09-22 | Biontech Ag | Compositions and methods for diagnosis and treatment of cancer |
| CN109689115A (zh) | 2016-06-10 | 2019-04-26 | 拜耳制药股份公司 | 放射性药物配合物 |
| JP2018035137A (ja) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ | 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用 |
| EA202090776A1 (ru) | 2017-10-23 | 2020-07-27 | Дзе Джонс Хопкинс Юниверсити | Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha) |
| JP7801207B2 (ja) * | 2019-07-08 | 2026-01-16 | ３ベー ファーマシューティカルズ ゲーエムベーハー | 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 |
| EP3763726A1 (en) * | 2019-07-08 | 2021-01-13 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
-
2021
- 2021-01-07 EP EP21150562.3A patent/EP4050018A1/en not_active Ceased
-
2022
- 2022-01-07 JP JP2023541262A patent/JP2024503635A/ja active Pending
- 2022-01-07 EP EP22700589.9A patent/EP4274836A1/en active Pending
- 2022-01-07 IL IL303926A patent/IL303926A/en unknown
- 2022-01-07 US US18/270,904 patent/US20240115745A1/en active Pending
- 2022-01-07 WO PCT/EP2022/050294 patent/WO2022148851A1/en not_active Ceased
- 2022-01-07 CN CN202280019455.0A patent/CN116940586A/zh active Pending
- 2022-01-07 AU AU2022205776A patent/AU2022205776A1/en active Pending
- 2022-01-07 KR KR1020237026402A patent/KR20230129260A/ko active Pending
- 2022-01-07 CA CA3206481A patent/CA3206481A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024503635A5 (https=) | ||
| JP2022541752A5 (https=) | ||
| IL289673B1 (en) | Compounds comprising a fibroblast activation protein ligand and use thereof | |
| JP2024503637A5 (https=) | ||
| US5759515A (en) | Polyvalent peptide pharmaceutical applications | |
| CN102458436B (zh) | 黑皮质素受体特异性肽 | |
| JP2017534676A5 (https=) | ||
| CA2121724A1 (en) | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction | |
| AU2024287205A1 (en) | Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy | |
| AU2018280861B2 (en) | Improved pharmacokinetics and cholecystokinin-2 receptor (CCK2R) targeting for diagnosis and therapy | |
| JP2025503451A5 (https=) | ||
| CA3194483A1 (en) | Novel cxcr4-targeting compounds | |
| US20210330824A1 (en) | Purification method and compositions | |
| ES2929507T3 (es) | Método para marcar una molécula directora biológica mediante conjugación con un radioisótopo adecuado para formación de imágenes por PET o SPECT | |
| US20250242064A1 (en) | Cxcr4-targeting compounds, and methods of making and using the same | |
| ES2309361T3 (es) | Conjugados de complejos de tc y restos de direccionamiento y su uso en diagnostico por rmn. | |
| US10548995B2 (en) | Radiolabelling method | |
| JPH0770178A (ja) | 胃腸運動刺激活性を有するモチリン類似ポリペプチド | |
| RU2022101907A (ru) | Соединения, содержащие лиганд белка активации фибробластов, и их применение | |
| US20110318827A1 (en) | Cysteine-Free Efficient Technetium (Tc) or Rhenium (Re) Chelating Peptide Tags and Their Use | |
| HK1226050A1 (en) | Purification method and compositions |